Moderna (MRNA) Stock Surges 16% on Flu Vaccine Data and Analyst Upgrades

TLDR

• Moderna stock surged over 16% after Phase 3 results for its mRNA flu vaccine (mRNA-1010) were published in the New England Journal of Medicine, showing it outperformed a standard-dose flu vaccine in adults 50 and older.
• Three analysts raised their price targets on Moderna following Q1 2026 earnings: Evercore ISI to $50, Goldman Sachs to $49, and Piper Sandler initiated with a Buy rating.
• A cluster of hantavirus cases linked to a cruise from Argentina to Cabo Verde briefly spiked attention on Moderna’s early-stage hantavirus program, though analysts say there is no meaningful revenue opportunity there.
• The FDA has set an August 5 PDUFA goal date for mRNA-1010, with filings also under review in Europe, Canada, and Australia.
• Pfizer and BioNTech halted recruitment for a major U.S. COVID vaccine trial for adults 50–64 due to low enrollment.

Moderna stock was trading around $56 on Thursday, up more than 16% on the day, fueled by a combination of strong clinical data, a wave of analyst upgrades, and some hantavirus headlines that caught investors’ attention.

Moderna, Inc., MRNA

The main driver was straightforward: Phase 3 trial results for Moderna’s mRNA flu vaccine candidate, mRNA-1010, were published in the New England Journal of Medicine. The data showed the vaccine met its prespecified superiority criterion against a licensed standard-dose seasonal flu vaccine in adults aged 50 and older.

That’s a meaningful bar to clear. Outperforming an approved vaccine in a peer-reviewed journal gives Moderna’s regulatory case a solid foundation heading into a key FDA decision.

The FDA has set August 5 as the PDUFA goal date for mRNA-1010. Regulatory filings are also under review in Europe, Canada, and Australia, making this a potential multi-market launch if approvals come through.

Analyst upgrades added fuel to the move. Evercore ISI lifted its price target from $35 to $50. Goldman Sachs raised its target from $43 to $49. Piper Sandler initiated coverage with a Buy rating. All three moves came in the wake of Moderna’s Q1 2026 earnings.

Hantavirus Headlines Added Noise

A hantavirus outbreak involving passengers on a Dutch-flagged cruise from Argentina to Cabo Verde briefly pushed Moderna higher in early trading. Eight cases were reported, including three deaths, with five confirmed as the Andes virus — the only hantavirus strain known to allow limited human-to-human transmission.

Evercore ISI flagged a Moderna collaboration with Korea University on hantavirus dating back to 2023, but was equally direct in its caution. The firm said it sees “no meaningful revenue opportunity” from the outbreak headlines and noted that Moderna’s hantavirus candidate “remains very early stage.” The stock, the analysts wrote, “tends to trade on outbreak headlines well beyond the underlying commercial implications.”

In short: the hantavirus news grabbed attention, but the flu vaccine data and analyst upgrades are what moved the stock.

Cruise Stocks Felt the Pressure

Cruise line stocks took a knock on the hantavirus news. Royal Caribbean fell about 2% on the day and Carnival dropped a similar amount. Norwegian Cruise Line Holdings was down nearly 3%. Viking Holdings and Lindblad Expeditions each fell around 2.5%.

On the competitive side, Pfizer and BioNTech halted enrollment for a large U.S. COVID vaccine trial targeting adults aged 50 to 64, citing low participation. That development may reinforce Moderna’s relative positioning in the next-generation vaccine space.

The broader market was supportive, with the S&P 500 up 0.71%, the Dow up 0.21%, and the Nasdaq up 1.16%.

Moderna’s stock closed the prior day at $48.79. The August 5 FDA decision date for mRNA-1010 is now the next major catalyst on the calendar.

The post Moderna (MRNA) Stock Surges 16% on Flu Vaccine Data and Analyst Upgrades appeared first on CoinCentral.